Nuclear is having a moment, and July marks a genuine inflection point for the uranium supply chain. With 38 countries having pledged to triple nuclear power by 2050, hyperscalers keep signing power purchase agreements to feed AI data centers, and Washington just moved uranium onto the U.S. Critical Minerals List in November 2025. The Section 232 uranium investigation status report is due this month, potentially catalyzing new import restrictions that favor domestic producers.
Long-term uranium contracting prices sit near a 14-year high around US$91.50/lb, and utilities are racing to lock in supply. For investors, the cleanest way to play this without taking single-reactor risk is a pure-play basket across mining and enrichment. Here are three U.S.-listed names that map directly to the policy and demand tailwinds heating up this month.
Cameco (CCJ)
Cameco (NYSE:CCJ | CCJ Price Prediction) is the tier-one anchor of any uranium book. The Saskatoon-based miner carries a $42.46 billion market cap and owns 49% of Westinghouse, giving it exposure to both the front-end fuel cycle and downstream reactor deployment. As of July 22, shares are down 8.22% year to date but up more than 16% over the past year and roughly 430% over five years, though the stock currently trades well off its 52-week high of $135.24.
The bull case rests on contracted volumes and rising realized prices. Q1 FY2026 uranium sales volumes rose 13% to 7.8 million pounds at a realized $65.45/lb, and 2026 guidance calls for 29 to 32 million pounds delivered at $85 to $89/lb, a step-change from $62.11/lb realized in 2025. Adjusted net earnings nearly tripled to $145.59 million in Q1, and the annual dividend was raised 50% to $0.24/share. Analysts carry a $132.13 target price with 9 Strong Buy and 10 Buy ratings.
Risk: Q1 revenue missed consensus by 25.62%, and the Key Lake mill bridge collapse plus an extended Q3 2026 maintenance shutdown could pressure delivery cadence. Q2 results land July 31, so keep an eye on the stock into month-end.
Uranium Energy (UEC)
Uranium Energy (NYSE:UEC) is the most direct U.S.-domestic mining play. The Corpus Christi-based ISR (in-situ recovery) producer carries a $5.24 billion market cap and runs a deliberately unhedged strategy, meaning every pound sold captures spot pricing. As of July 22, shares trade around $9.68, up nearly 19% over the past year but down more than 26% year-to-date. Analysts see upside to $18.25.
The unhedged posture is already paying off. In Q2 FY2026, UEC sold 200,000 pounds at $101/lb, more than 25% above the quarterly spot average of $80.76/lb. Management then deliberately booked zero sales in Q3 to preserve pricing optionality, sitting on 1.456 million pounds of U3O8 valued at $127 million. The balance sheet is a fortress: $794 million in liquid assets, $488 million in cash, zero debt. Burke Hollow just came online as the largest greenfield ISR project to enter U.S. production in over a decade. If Section 232 lands with teeth this month, UEC is arguably the single most direct US-domestic beneficiary.
Risk: No revenue in Q3, a rising total cost per pound of $54.61 (up from $44.14), and single-commodity exposure. The stock is volatile.
Centrus Energy (LEU)
Centrus Energy (NYSE:LEU) is the differentiated pick: the only US-owned uranium enricher. That matters because advanced reactors, small modular reactors, and many AI-data-center-linked designs require HALEU (high-assay low-enriched uranium), a fuel Russia currently dominates. On July 22, Centrus traded around $174, down 36% year to date from a 52-week high of $464.25, offering a re-rating setup as the enrichment story reasserts itself. It rallied nearly 15% in the past week.
Q1 FY2026 was a genuine blowout: adjusted diluted EPS of $1.05 versus the 27-cent consensus, a 288.89% surprise, and Technical Solutions revenue up 47% on the DOE HALEU Operation Contract. Management raised 2026 revenue guidance to $450 million to $500 million and sits on $1.87 billion in cash. The strategic backdrop is even better: a $900 million DOE HALEU production task order, a $3.8 billion total backlog extending to 2040, and a $2.3 billion contingent LEU backlog. The Palantir partnership has already surfaced roughly $300 million in cost savings. Analysts target $274.36 with nine Buy and two Strong Buy ratings.
Risk: Execution on the Piketon and Oak Ridge centrifuge buildout, and DOE funding subject to appropriations. Q1 operating income collapsed 96% year-over-year as advanced-tech costs stepped up.
What to Watch Next
Three catalysts define the July setup: the Section 232 status report, Cameco’s July 31 Q2 earnings, and any incremental hyperscaler nuclear PPA announcements. If the policy report lands with domestic-sourcing teeth, UEC and LEU get the sharpest re-rating, while CCJ remains the lower-beta way to own the theme. The uranium bull cycle is early-innings, and this basket covers mining, contracting, and enrichment without touching utility risk.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks